Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas H Scheel

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
European Journal of Cancer (Oxford, England : 1990)|December 15, 2022
Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitorsRichard Riedel, Jana Fassunke, Hannah L Tumbrink, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 7, 2019
"Interchangeability" of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracyEmina Torlakovic, Hyun J Lim, Julien Adam, et al.
Science Translational Medicine|June 16, 2017
Drugging the catalytically inactive state of RET kinase in RET-rearranged tumorsDennis Plenker, Maximilian Riedel, Johannes Brägelmann, et al.
Blood|April 7, 2016
B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in miceGero Knittel, Paul Liedgens, Darya Korovkina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2016
Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR InhibitorsSandra Ortiz-Cuaran, Matthias Scheffler, Dennis Plenker, et al.
The Journal of Clinical Investigation|August 22, 2023
Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancerFlorian Malchers, Lucia Nogova, Martijn Ha van Attekum, et al.
Nature Communications|November 9, 2018
Overcoming EGFR<sup>G724S</sup>-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitorsJana Fassunke, Fabienne Müller, Marina Keul, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 13, 2019
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical TrialSebastian Michels, Bartomeu Massutí, Hans-Ulrich Schildhaus, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 4, 2019
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic PathwaysMatthias Scheffler, Michaela A Ihle, Rebecca Hein, et al.
JCO Precision Oncology|September 11, 2020
Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung CancerSebastian Michels, Carina Heydt, Bianca van Veggel, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
European Journal of Cancer (Oxford, England : 1990)|December 15, 2022
Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitorsRichard Riedel, Jana Fassunke, Hannah L Tumbrink, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 7, 2019
"Interchangeability" of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracyEmina Torlakovic, Hyun J Lim, Julien Adam, et al.
Science Translational Medicine|June 16, 2017
Drugging the catalytically inactive state of RET kinase in RET-rearranged tumorsDennis Plenker, Maximilian Riedel, Johannes Brägelmann, et al.
Blood|April 7, 2016
B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in miceGero Knittel, Paul Liedgens, Darya Korovkina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2016
Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR InhibitorsSandra Ortiz-Cuaran, Matthias Scheffler, Dennis Plenker, et al.
The Journal of Clinical Investigation|August 22, 2023
Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancerFlorian Malchers, Lucia Nogova, Martijn Ha van Attekum, et al.
Nature Communications|November 9, 2018
Overcoming EGFR<sup>G724S</sup>-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitorsJana Fassunke, Fabienne Müller, Marina Keul, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 13, 2019
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical TrialSebastian Michels, Bartomeu Massutí, Hans-Ulrich Schildhaus, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 4, 2019
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic PathwaysMatthias Scheffler, Michaela A Ihle, Rebecca Hein, et al.
JCO Precision Oncology|September 11, 2020
Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung CancerSebastian Michels, Carina Heydt, Bianca van Veggel, et al.
Pageof 5